PECULIARITIES OF c-Myc PROTEIN EXPRESSION IN ENDOMETRIAL CARCINOMAS WITH SIGNS OF AN AGGRESSIVE COURSE OF THE DISEASE
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-21-4-2019-g.8452Keywords:
aneuploidy, c-Myc, E2F1, endometrial cancer, epithelial-mesenchymal transition, proliferationAbstract
Endometrial cancer (EC) is characterized by marked clinical and morphological heterogeneity and variability of the course of the disease, which necessitates the search for molecular biological markers that most accurately reflect the aggressiveness of the tumor. The c-Myc protein is considered to be one of the promising markers, and therefore, a detailed study of its role in determining the malignant potential of endometrial cancer is relevant. Aim: to determine the association of c-Myc protein expression in endometrial carcinomas with such indicators of the aggressive course of the malignant process as proliferative activity, expression of epithelial-mesenchymal transition markers and ploidy of tumor cells. Object and methods: The study was conducted on tumor tissue samples from 55 patients with FIGO I–II stage of the endometrial carcinoma. Marker expression was assessed immunohistochemically using primary antibodies to c-Myc, E2F1, E-cadherin, beta-catenin and vimentin proteins by calculating the label index (LI), which reflects the percentage of positively stained cells. The DNA content and proliferative potential of tumor cells were evaluated by flow cytometry, determining the DNA index (iDNA) and proliferation index (PI, %), respectively. Results: A positive correlation between the expression of c-Myc protein and transcription factor E2F1, which controls the transition from G1-to the S-phase of the cell cycle (r = 0.58; p < 0.05), was determined. It was found that in tumors with a high level of c-Myc (LI > 10.0%), more intensive proliferation is observed than in carcinomas with a low level of this marker (PI 33.4 ± 2.5 and 26.1 ± 2.4% respectively; p < 0.05). No significant differences were found in the expression level of adhesion proteins for E-cadherin and beta-catenin in carcinomas with high and low levels of c-Myc. At the same time, it was found that the expression of the vimentin mesenchymal cell marker was lower in carcinomas with a high level of c-Myc compared with tumors with a low level (LI 20.7 ± 6.4 and 44.6 ± 6.2%, respectively; p < 0, 05). There was an increase in c-Myc expression in aneuploid tumors compared with diploid (LI 20.8 ± 9.1 and 6.7 ± 2.2%, respectively; p < 0.05), which was associated with a low degree of differentiation and deep tumor invasion in myometrium. Conclusion: High expression of c-Myc protein in endometrial carcinomas is associated with increased proliferative activity, signs of an incomplete epithelial-mesenchymal transition and aneuploid status of tumors, which indicates the important role of this protein in the progression of the malignant process in the endometrium and may become the basis for its use for identifying tumors with more aggressive potential.
References
Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014; 15 (7): e268–78.
Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 2018; 29 (5): 1180–88.
Cosgrove CM, Tritchler DL, Cohn DE, et al. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol 2018; 148 (1): 174–80.
Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer — combined analysis of the PORTEC cohorts. Clin Cancer Res 2016; 22 (16): 4215–24.
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497 (7447): 67–73.
Zhang Q, Xu P, Lu Y, et al. Correlation of MACC1/c-Myc expression in endometrial carcinoma with clinical/pathological features or prognosis. Med Sci Monit 2018; 24: 4738–44.
Yoshida GJ. Emerging roles of Myc in stem cell biology and novel tumor therapies. J Exp Clin Cancer Res 2018; 37 (1): 173.
Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther 2018; 3: 5.
Schaub FX, Dhankani V, Berger AC, et al. Pan-cancer alterations of the MYC oncogene and its proximal network across the Cancer Genome Atlas. Cell Syst 2018; 6 (3): 282–300.e2.
Kalkat M, De Melo J, Hickman KA, et al. MYC deregulation in primary human cancers. Genes (Basel) 2017; 8 (6): E151.
Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 2009; 106 (12): 4834–9.
Buchynska LG, Brieieva OV, Iurchenko NP. Assessment of Her-2/neu, с-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas. Exp Oncol 2019; 41 (2): 138–43.
Prochownik EV, Li Y. The ever expanding role for c-Myc in promoting genomic instability. Cell Cycle 2007; 6 (9): 1024–9.
Prochownik EV. c-Myc: linking transformation and genomic instability. Curr Mol Med 2008; 8 (6): 446–58.
Kuzyk A, Mai S. c-MYC-induced genomic instability. Cold Spring Harb Perspect Med 2014; 4 (4): a014373.
Matsumura I, Tanaka H, Kanakura Y. E2F1 and c-Myc in cell growth and death. Cell Cycle 2003; 2 (4): 333–8.
Vazquez-Martin A, Anatskaya OV, Giuliani A, et al. Somatic polyploidy is associated with the upregulation of c-MYC interacting genes and EMT-like signature. Oncotarget 2016; 7 (46): 75235–60.
Cho KB, Cho MK, Lee WY, Kang KW. Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells. Cancer Lett 2010; 293 (2): 230–9.
Coller HA, Forman JJ, Legesse-Miller A. ‘Myc’ed messages’: myc induces transcription of E2F1 while inhibiting its translation via a microRNA polycistron. PLoS Genetics 2007; 3 (8): p.e146.
Leung JY, Ehmann GL, Giangrande PH, Nevins JR. A role for Myc in facilitating transcription activation by E2F1. Oncogene 2008; 27 (30): 4172–9.
Yin S, Cheryan VT, Xu L, et al. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. PLoS One 2017; 12 (8): e0183578.
Makker A, Goel MM. Tumor progression, metastasis, and modulators of epithelial-mesenchymal transition in endometrioid endometrial carcinoma: an update. Endocr Relat Cancer 2016; 23 (2): R85–R111.
Mirantes C, Espinosa I, Ferrer I, et al. Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. Hum Pathol 2013; 44 (10): 1973–81.
Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell 2016; 166 (1): 21–45.
Nesina IP, Iurchenko NP, Buchynska LG. Markers of the epithelial-mesenchymal transition in cells of endometrial carcinoma. Exp Oncol 2018; 40 (3): 218–22.
Wilson MR, Reske JJ, Holladay J, et al. ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion. Nat Commun 2019; 10 (1): 3554.
Wang X, Enomoto A, Asai N, et al. Collective invasion of cancer: Perspectives from pathology and development. Pathol Int 2016; 66(4): 183–92.
Oltmann J, Heselmeyer-Haddad K, Hernandez LS, et al. Aneuploidy, TP53 mutation, and amplification of MYC correlate with increased intratumor heterogeneity and poor prognosis of breast cancer patients. Genes Chromosomes Cancer 2018; 57 (4): 165–75.
